ArriVent BioPharma, Inc. announced on October 19, 2026, that the results of the FURTHER Phase 1b study (FURMO-002; NCT05364073) regarding firmonertinib have been published in the journal Cancer Cell. The filing details the findings regarding firmonertinib’s potential application for advanced non-small cell lung cancer (NSCLC) patients with EGFR PACC mutations.
The publication highlights that EGFR PACC-mutant NSCLC accounts for approximately 12% of EGFR-mutant tumors. Currently, there is no established targeted standard of care for this patient population, who are typically treated with therapies not designed for their specific biology.
Key clinical data from the study includes:
- Overall Response Rate (ORR): 43% at the 160 mg dose and 68% at the 240 mg dose.
- Progression-Free Survival (PFS): Median PFS was 11.1 months at 160 mg and 16.0 months at 240 mg.
- Intracranial Activity: A confirmed intracranial ORR of 47% (8 out of 17 patients), including a 41% complete response rate among patients with baseline brain metastases.
- Molecular Response: 80% of evaluable patients achieved complete molecular response by Cycle 3.
ArriVent is currently evaluating firmonertinib versus an investigator’s choice of osimertinib or afatinib in a global Phase 3 trial (FURMO-006; NCT07185997) for first-line treatment of locally advanced or metastatic EGFR PACC-mutant NSCLC.
